The Biosafety Level-3 (BL-3) Core Facility is designed to provide an efficient, cost-effective, and safe environment for CFAR and other investigators involved in AIDS and AIDS-related research such that both ongoing projects will benefit and new collaborations will be fostered. Since culture of biohazardous pathogens including HIV, SIV, HTLV-I and virulent M. tuberculosis is an absolute requirement for many CFAR investigators, this facility is essential. The new BL-3 Facility (1127 sq ft) is scheduled for completion in October 1993, and is located on the 10th floor of the Biomedical Research Building, in the Division of Infectious Disease. The Facility has recently been equipped to the greater extent by the CWRU School of Medicine. Equipment includes 5 laminar flow hoods, centrifuges, incubators, -70C freezers, microscopes, thermal cycler and ELISA reader. The Facility is comprised of 6 rooms, the 3 largest for biohazardous activities. One room will be devoted to research involving virulent M. tuberculosis and another to HIV, SIV, and HTLV-I. Other rooms house common equipment. The BL-3 Core Facility will be administered by a BL-3 Advisory Group comprised of members of the CFAR; Dr. Rich (Director of the BL-3 Core Facility), Dr. LeGrice, and De. Lederman. Dr. Rich's laboratory is adjacent to the BL-3 Facility. Projects performed in the BL-3 Facility will be established beginning in funding year 02 to cover costs of the Facility such that by year 05, 70% of these will be generated by such fees. Multidisciplinary collaboration will be fostered by the BL-3 Core Facility by three main mechanisms: 1) Through interactions among users of the facility; 2) Through services rendered by a full-time research assistant in the facility including viral stock preparation, HIV infections of cells, p24 ELISAs, and teaching of these techniques to new investigators. 3) Quarterly meetings by all users and interested faculty discussing results obtained from experiments performed in the facility.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
1P30AI036219-05
Application #
2778810
Study Section
Project Start
Project End
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Tomas, Myreen E; Mana, Thriveen S C; Wilson, Brigid M et al. (2018) Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother 62:
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Sahmoudi, Karima; Abbassi, Hassan; Bouklata, Nada et al. (2018) Immune activation and regulatory T cells in Mycobacterium tuberculosis infected lymph nodes. BMC Immunol 19:33
Webel, Allison R; Moore, Shirley M; Longenecker, Chris T et al. (2018) Randomized Controlled Trial of the SystemCHANGE Intervention on Behaviors Related to Cardiovascular Risk in HIV+ Adults. J Acquir Immune Defic Syndr 78:23-33
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Eckard, Allison Ross; O'Riordan, Mary Ann; Rosebush, Julia C et al. (2018) Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth. Antivir Ther 23:315-324
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150

Showing the most recent 10 out of 539 publications